Glycine Receptor Alpha1 IgG, Cell Binding Assay, Spinal Fluid
Use
This test is useful for evaluating patients with suspected autoimmune stiff-person spectrum disorders such as stiff-person syndrome, stiff-limb syndrome, stiff trunk syndrome, and progressive encephalomyelitis with rigidity and myoclonus (PERM) using spinal fluid specimens. The presence of antibodies targeting the glycine receptor alpha1 subunit (GlyRa1) is indicative of these conditions, especially in patients who are seronegative for GAD65-IgG.
Special Instructions
Not provided.
Limitations
Negative results do not exclude autoimmune stiff-person spectrum disorders or cancer. The test was developed and its performance characteristics determined by Mayo Clinic in compliance with CLIA requirements, but it has not been cleared or approved by the FDA. Seropositivity is detected more frequently in GlyRa1-IgG antibody positive patients compared to those seropositive for GAD65-IgG alone. Potential paraneoplastic causes should also be considered.
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
LOINC Codes
- 96497-3 - GlyRa-1 IgG CSF Ql CBA IFA
- 96497-3 - GlyRa-1 IgG CSF Ql CBA IFA
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
Sterile vial
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |